This $475,475 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts. The goal of the award is to evaluate a small molecule inhibitor of the USP30 enzyme as a potential neuroprotective therapy for Parkinson's disease. The research will assess whether inhibiting USP30 can enhance mitophagy, the selective degradation of dysfunctional mitochondria, and thereby protect dopaminergic neurons from the toxicity of alpha-synuclein. The 2-year project will utilize a slowly progressive mouse model of Parkinson's disease to test the efficacy and mechanisms of this therapeutic strategy. If successful, these preclinical results could support the advancement of this USP30 inhibitor or related compounds towards clinical trials for neuroprotection in Parkinson's disease.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $475.5k | 8/31/23 |